Uncovering an antifibrotic Prrx1 -lineage mesenchymal cell subpopulation in fibrotic lungs
Disease Models & Mechanisms · 2025
DOI: 10.1242/dmm.052179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2025. Verfasst von Meline Homps-Legrand und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Inserm, Centre de Recherche sur l'Inflammation, F-75018 Paris, France. Hauptthemen laut MEDLINE: Homeodomain Proteins, Cell Lineage, Mesenchymal Stem Cells, Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Chancellerie des Universités de Paris, Association Fibrose Pulmonaire France.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a rare and fatal lung disease caused by progressive damage to alveolar epithelial cells, leading to abnormal activation of mesenchymal cells. The PRRX1 transcription factor (TF) has been found to be reactivated in IPF and was previously identified as a key mesenchymal TF in pulmonary fibrosis. In this study, we utilized the Prrx1:CreERT2; Rosa26iTomato murine transgenic line to further characterize the Prrx1-positive cell lineage in healthy and fibrotic lungs. The Prrx1 limb enhancer (Prrx1enh) was undetectable by immunohistochemistry in uninjured lung tissue. However, during the fibrotic phase in the bleomycin model of pulmonary fibrosis, Prrx1enh became activated, marking a population of cells that differentiated into mesenchymal progeny. To investigate further, we conducted reprogramming of these subpopulations after conditional and inducible Prrx1 loss of function. Prrx1 loss in these cells led to worsened fibrosis, indicating that this specific cell population has antifibrotic properties. Our findings reveal a previously unrecognized subpopulation of Prrx1-positive mesenchymal cells that are activated during fibrogenesis. These cells could serve as targets for future therapies aimed at mitigating fibrotic progression in IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, Inserm, Centre de Recherche sur l'Inflammation, F-75018 Paris, France.
- Hôpital Bichat, AP-HP, Service de Pneumologie, Allergologie et Transplantation, Centre Constitutif du Centre de Référence des Maladies Pulmonaires Rares, FHU INFIRE, 75018 Paris, France.
ORCID-Profile: Arnaud A Mailleux
Förderung
- Agence Nationale de la Recherche
- Chancellerie des Universités de Paris
- Association Fibrose Pulmonaire France
- Fonds de Recherche en Santé Respiratoire
- Fondation pour la Recherche Médicale
- Institut National de la Santé et de la Recherche Médicale
Zitieren
APA
Homps-Legrand, M., Jaillet, M., Deneuville, L., Gautier, G., Crestani, B., & Mailleux, A. A. (2025). Uncovering an antifibrotic Prrx1 -lineage mesenchymal cell subpopulation in fibrotic lungs. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052179
Vancouver
Homps-Legrand M, Jaillet M, Deneuville L, Gautier G, Crestani B, Mailleux AA. Uncovering an antifibrotic Prrx1 -lineage mesenchymal cell subpopulation in fibrotic lungs. Disease Models & Mechanisms. 2025. doi:10.1242/dmm.052179
BibTeX
@article{HompsLegrand2025,
author = {Homps-Legrand, Meline and Jaillet, Madeleine and Deneuville, Lou and Gautier, Gregory and Crestani, Bruno and Mailleux, Arnaud A},
title = {Uncovering an antifibrotic Prrx1 -lineage mesenchymal cell subpopulation in fibrotic lungs},
journal = {Disease Models & Mechanisms},
year = {2025},
doi = {10.1242/dmm.052179}
}
EUVIMED